Perimenopause is LOOPy!!

Identifying and managing the Luteal Out-of-Phase Phenomenon in Perimenopause

Chief Concern

A 51-year-old perimenopausal woman with well-controlled hyperlipidemia presents for management of hormonal fluctuations and metabolic optimization, with particular attention to thyroid hormone replacement in the context of extreme estrogen variability.

History of Present Illness

The patient is a perimenopausal woman experiencing irregular menstrual cycles with her last menstrual period 41 days prior, characterized by heavy flow lasting one week followed by spotting. She reports classic perimenopausal symptoms including mood lability, intermittent hot flashes with night sweats requiring clothing removal during sleep, breast tenderness and fullness, bloating, and sleep disturbances with early morning awakening at 3 AM with difficulty returning to sleep.

She describes significant gastroesophageal reflux symptoms with throat irritation and intermittent tingling sensations. Intermenstrual spotting occurs occasionally. The patient has experienced recent significant family stress related to her husband's recent cancer diagnosis and treatment over the past year, which she identifies as a contributing factor to her symptoms.

Regarding weight management, the patient successfully lost 10% of her body weight using a GLP-1 receptor agonist (tirzepatide 2.5 mg) approximately 3 months over one year ago. She discontinued therapy 6 months prior to assess weight maintenance without pharmacologic support. She has successfully maintained her weight loss through regular strength training, healthy eating patterns, and intermittent fasting, though she acknowledges frequent snacking. She reports feeling stronger and has been focusing on building muscle mass.

Past Medical History

- Hyperlipidemia (well-controlled)

- Uterine fibroids

- most recent pregnancy at age 44, G3P3

-autoimmune thyroiditis

- history of overweight

Current Medications and Supplements

Estradiol transdermal patch 0.05 mg twice weekly, micronized progesterone 200 mg nightly, red yeast rice supplement 2 capsules nightly, levothyroxine 88 mcg daily, vitamin D3 5000 IU daily, iron supplement, zinc 50 mg daily, berberine 1 capsule daily, magnesium glycinate, multivitamin for women over 50, dual probiotic regimen (spore-based and women's formula), boron vaginal suppositories for recent BV infection

Social History

Works in entertainment/media industry with on-camera appearances. Regular gym attendance with focus on strength training. Generally healthy dietary habits with acknowledged frequent snacking, consumes kombucha every other day. Lives with husband and three children.

Physical Examination

Well-appearing woman in no acute distress

Laboratory Data - Current (January 2026)

- Estradiol: 1,930 pg/mL (extremely elevated)

- Sex hormone binding globulin: elevated

- FSH: appropriately suppressed

- TSH, free T and free T3: within normal range

- Hemoglobin A1c: improved from 5.8 (May 2024) to current level below prediabetic threshold

- Fasting glucose: 82 mg/dl

- Cortisol: 24.9 (high but improved from previously elevated level of 31)

- DHEA: significantly low

- Testosterone: mildly low

- Total cholesterol: significantly improved

- ApoB: significantly improved

- HDL: 60s mg/dL (excellent)

- Triglycerides: slightly elevated to 154 mg/dl

- C-reactive protein, hs: 0.4

- Hemoglobin: normal

- Ferritin: optimal at 85 (previously 25)

- Zinc: optimal at 130

- B vitamins: optimal

- Magnesium: improved from previously low

- Albumin: decreased (consistent with high estrogen state)

- notably, hCG is negative (even though she feels pregnant!)

Historical Estradiol Levels (5-year tracking)

February 2021: 132 pg/mL → subsequent readings: 47, 79, undetectable (2 years prior), ~100, 768, 948 pg/mL → current: 1,930 pg/mL

Pattern demonstrates progressive hormonal instability with increasingly extreme fluctuations over the past 18 months, consistent with advancing perimenopause.

Assessment and Clinical Discussion

The Luteal Out-of-Phase Phenomenon

This patient exemplifies the "luteal out-of-phase" or "perimenopausal loop" phenomenon, a poorly recognized but clinically significant pattern in late perimenopause. In this phenomenon, the ovaries continue producing excessive and erratic estrogen despite exogenous hormone replacement, creating extreme hormonal fluctuations that cannot be adequately suppressed by standard transdermal estradiol replacement.

The pathophysiology involves dysregulation of the hypothalamic-pituitary-ovarian axis as ovarian reserve declines. Rather than transitioning smoothly to menopause, some women experience paradoxical ovarian hyperstimulation with intermittent production of supraphysiologic estrogen levels. The patient's estradiol level of 1,930 pg/mL represents approximately 10-20 times normal follicular phase levels and rivals levels seen in ovarian hyperstimulation syndrome or estrogen-producing tumors.

The 5-year tracking of estradiol levels demonstrates the progressive nature of this phenomenon: starting at 132 pg/mL in early perimenopause, fluctuating to undetectable levels, then escalating near levels of 1,000 pg/mL and now 1,930 pg/mL. This pattern of increasingly extreme swings is characteristic of the luteal out-of-phase state.

The appropriately suppressed FSH in the context of extremely elevated estradiol confirms that the hypothalamic-pituitary axis is responding to the high estrogen through negative feedback, yet the ovaries continue autonomous estrogen production. This creates a "loop" where standard hormone replacement strategies fail to stabilize the system.

Clinical Manifestations of the Loop Phenomenon

The patient's symptoms directly correlate with her extreme estrogen elevation:

- Bloating and water retention (2.6 pounds water weight gain)

- Breast tenderness and fullness

- Mood lability and emotional dysregulation

- Breakthrough bleeding and spotting

- Decreased albumin (estrogen affects hepatic protein synthesis)

- Slightly elevated triglycerides (estrogen effects on hepatic lipid metabolism)

- Sleep disturbances (estrogen affects sleep architecture)

- Gastroesophageal reflux (estrogen affects lower esophageal sphincter tone)

The irregular menstrual pattern (41 days since last period, heavy flow followed by spotting) reflects anovulatory cycles with unopposed estrogen proliferation of the endometrium followed by breakthrough bleeding.

Thyroid Hormone Replacement in the Context of Extreme Estrogen Fluctuations

This case highlights a critical but underappreciated interaction: the impact of fluctuating estrogen levels on thyroid hormone bioavailability and metabolism in women on levothyroxine replacement.

Mechanisms of Estrogen-Thyroid Interaction:

1. Thyroid Binding Globulin (TBG) Elevation: Estrogen stimulates hepatic production of TBG, the primary carrier protein for thyroid hormones. The patient's elevated sex hormone binding globulin suggests concurrent TBG elevation. Increased TBG binds more circulating thyroid hormone, reducing free (bioavailable) T4 and T3 despite normal TSH.

2. Hepatic Metabolism: High estrogen states alter hepatic enzyme activity, potentially affecting thyroid hormone metabolism and clearance.

3. Peripheral Conversion: Estrogen may influence peripheral conversion of T4 to T3, affecting tissue-level thyroid hormone availability.

4. TSH Feedback Sensitivity: The hypothalamic-pituitary-thyroid axis may respond differently to thyroid hormone levels in high estrogen states.

Clinical Implications for This Patient:

The patient's TSH remains "very healthy" (within normal range), but this may not reflect true tissue-level thyroid hormone sufficiency during her extreme estrogen peaks. Women on stable levothyroxine doses can develop functional hypothyroidism during estrogen surges despite normal TSH, manifesting as:

- Fatigue (which the patient reports)

- Weight gain (patient gained 6.4 pounds, though 2.6 pounds is water)

- Sleep disturbances (early morning awakening at 3 AM)

- Mood changes (mood lability attributed to perimenopause may be partially thyroid-mediated)

- Metabolic slowing (patient notes difficulty maintaining weight despite healthy habits)

The challenge is that as estrogen levels fluctuate wildly in the luteal out-of-phase pattern, thyroid hormone requirements may vary significantly. During estrogen peaks (1,930 pg/mL), TBG elevation may necessitate higher levothyroxine doses. During estrogen nadirs (previously undetectable), the same dose may be excessive.

Management Strategy for Thyroid Replacement in Perimenopausal Loop:

The key is recognizing that thyroid hormone replacement cannot be optimally managed until the underlying hormonal chaos is controlled. The management plan appropriately prioritizes:

1. Stabilize the Hormonal Loop First: Initiation of drospirenone (Slynd) to suppress ovulation and prevent the extreme estrogen surges. This synthetic progestin provides consistent ovarian suppression, breaking the loop phenomenon.

2. Monitor Thyroid Function During Transition: As hormonal stabilization occurs with drospirenone, thyroid hormone requirements may change. The plan appropriately includes monitoring thyroid function as estrogen levels stabilize and reassessing after hormonal stabilization.

3. Consider Dose Adjustment if Symptomatic: The plan includes consideration of slight levothyroxine increase if hypothyroid symptoms develop, recognizing that current "normal" TSH may not reflect optimal replacement during high estrogen states.

4. Reassess After Stabilization: Once the luteal out-of-phase phenomenon is controlled and estrogen levels stabilize, thyroid function should be comprehensively reassessed to establish optimal long-term levothyroxine dosing.

Alternative Management Approach:

If the patient chooses not to use drospirenone, the plan includes increasing micronized progesterone to 300-400 mg nightly. Higher-dose progesterone may provide some ovarian suppression and endometrial protection, though likely less effective than synthetic progestins for breaking the loop phenomenon. This approach would require more vigilant thyroid monitoring given continued estrogen fluctuations.

Weight Management in the Context of Hormonal and Metabolic Complexity

The patient's weight management history demonstrates successful GLP-1 agonist therapy with 10% body weight reduction, followed by successful maintenance off therapy for 6 months through lifestyle interventions. Her current weight gain (6.4 pounds since May) requires nuanced interpretation:

- 2.6 pounds water weight (estrogen-mediated fluid retention)

- 2.4 pounds fat gain

- 3.2 pounds muscle gain (net positive given strength training focus)

The body composition changes are actually favorable (increased muscle mass, stable visceral fat in healthy 5-6 range), but the patient feels best at 139-143 pounds versus current 145.4 pounds.

The management plan appropriately recognizes that weight management will become easier once hormonal fluctuations stabilize. The extreme estrogen levels promote fluid retention, increase appetite through multiple mechanisms, and may reduce metabolic rate through thyroid hormone binding effects. The plan includes option to resume tirzepatide as needed, recognizing its dual benefits for glucose control and diuretic effect in addition to weight management.

Endometrial Protection and Cancer Risk

The extreme estrogen elevation (1,930 pg/mL) with irregular bleeding raises significant concern for endometrial hyperplasia and potential progression to endometrial cancer. The patient's history of uterine fibroids adds additional concern for fibroid growth under high estrogen stimulation.

The management plan appropriately includes:

- Pelvic ultrasound to evaluate endometrial thickness and fibroid changes

- Gynecologic examination within 2-3 weeks

- Progestin therapy (drospirenone) for endometrial protection

- Consideration of increased progesterone dosing (300 -400 mg nightly) if not using drospirenone

- Ensuring current mammography given prolonged high estrogen exposure

Additional Metabolic Considerations

Prediabetes Risk: The patient's A1c improved from 5.8 to below 5.7, remaining below prediabetic threshold despite significant family stress. This improvement likely reflects her successful weight maintenance, berberine supplementation, and intermittent fasting practice. However, high estrogen states can affect glucose metabolism through multiple mechanisms, and stress-related cortisol elevation (though improved from previous levels) may contribute to glycemic excursions. The plan appropriately continues berberine with consideration of dose escalation.

Lipid Management: The significant improvement in cholesterol and ApoB levels reflects successful management with colesevelam. The slight triglyceride elevation is consistent with high estrogen effects on hepatic lipid metabolism and should improve with hormonal stabilization.

Micronutrient Optimization: The patient demonstrates excellent adherence to supplementation with optimal levels of zinc, ferritin, B vitamins, and improved magnesium. Vitamin D at 44 ng/mL is slightly below optimal (45-80 ng/mL target), appropriately addressed with dose escalation to alternating 10,000/5,000 IU schedule.

DHEA Deficiency: The significantly low DHEA level may contribute to fatigue, mood changes, and difficulty maintaining muscle mass. This was not addressed in the current plan but warrants consideration for DHEA supplementation, particularly given the patient's focus on strength training and body composition optimization.

Monitoring Strategy

The patient would benefit from:

- Repeat estradiol, progesterone, and thyroid function testing 4-6 weeks after initiating drospirenone

- Consideration of Mira fertility tracker for real-time hormone monitoring to correlate symptoms with hormonal fluctuations

- Body composition monitoring to track changes with hormonal stabilization

- Continued A1c and lipid monitoring

- Pelvic ultrasound and gynecologic evaluation as planned

Clinical Pearls

1. The luteal out-of-phase phenomenon represents a distinct clinical entity in late perimenopause requiring progestin-based ovarian suppression rather than standard estrogen replacement escalation.

2. Extreme estrogen fluctuations in perimenopause can significantly affect thyroid hormone bioavailability in women on levothyroxine replacement, despite normal TSH values.

3. Thyroid hormone replacement cannot be optimally managed until underlying hormonal chaos is controlled in the perimenopausal loop phenomenon.

4. Weight management becomes significantly more challenging during extreme hormonal fluctuations, and patients should be counseled that stabilization will facilitate weight control.

5. Successful GLP-1 agonist therapy with maintained weight loss off medication demonstrates that these agents can be used as a bridge to sustainable lifestyle modification rather than requiring lifelong therapy.

6. Body composition analysis provides more meaningful information than weight alone, particularly in perimenopausal women focusing on strength training.

7. Extreme estrogen elevations require urgent endometrial evaluation and protection to prevent hyperplasia and malignancy.

This case presentation illustrates several important evidence-based concepts in perimenopausal management. The luteal out-of-phase phenomenon, while not widely discussed in standard texts, represents a clinically significant pattern where standard hormone replacement strategies fail due to continued autonomous ovarian estrogen production. The interaction between estrogen and thyroid hormone binding proteins is well-established, with estrogen increasing thyroid binding globulin production and potentially necessitating levothyroxine dose adjustments in women starting estrogen therapy or experiencing estrogen fluctuations.

The patient's successful weight maintenance after GLP-1 agonist discontinuation is noteworthy, as emerging evidence suggests that some patients can maintain weight loss achieved with these medications through lifestyle interventions, particularly when the initial therapy facilitates establishment of healthier eating patterns and exercise habits. Her body composition changes (increased muscle mass despite modest weight gain) demonstrate the importance of looking beyond scale weight in perimenopausal women engaged in strength training.

The management strategy of using synthetic progestins (drospirenone) to suppress ovulation and break the hormonal loop is supported by evidence showing that progestins can effectively suppress ovarian function in perimenopause, though this approach is less commonly discussed than standard menopausal hormone therapy. The plan to reassess thyroid function after hormonal stabilization recognizes that thyroid hormone requirements may change significantly once estrogen levels are controlled.

This case highlights the reason why I trend estradiol levels during perimenopause despite the guidelines which state that hormone lab levels are not recommended. For the woman who is experiencing wild hormone fluctuations, the objective data of her lab levels is very validating to her experience of perimenopausal chaos. There is therapeutic value to reassuring a woman that she has valid reason to feel she is on a bit of a hormonal roller coaster! As a physician who has personally experienced the IVF complication of ovarian hyper stimulation syndrome and then had a loopy perimenopause, I hope this case helps other women and practitioners that are experiencing similar symptoms.